Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Literature review of human papillomavirus vaccine acceptability among women over 26 years.

Black LL, Zimet GD, Short MB, Sturm L, Rosenthal SL.

Vaccine. 2009 Mar 10;27(11):1668-73. doi: 10.1016/j.vaccine.2009.01.035. Epub 2009 Feb 3. Review.

PMID:
19195491
2.

Human papillomavirus vaccine: a paradigm shift for pediatricians.

Jenson HB.

Curr Opin Pediatr. 2009 Feb;21(1):112-21. doi: 10.1097/MOP.0b013e3283207f93. Review.

PMID:
19242247
3.

Chapter 24: Psychosocial aspects of vaccine acceptability.

Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/201-9. Review.

PMID:
16950008
4.

Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean.

Winkler JL, Wittet S, Bartolini RM, Creed-Kanashiro HM, Lazcano-Ponce E, Lewis-Bell K, Lewis MJ, Penny ME.

Vaccine. 2008 Aug 19;26 Suppl 11:L73-9. doi: 10.1016/j.vaccine.2008.05.027. Review.

PMID:
18945404
5.

Economic evaluation of human papillomavirus vaccination in developed countries.

Brisson M, Van de Velde N, Boily MC.

Public Health Genomics. 2009;12(5-6):343-51. doi: 10.1159/000214924. Epub 2009 Aug 11. Review.

PMID:
19684446
6.

Efficacy of human papillomavirus vaccines: a systematic quantitative review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.

Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100. Review.

PMID:
19823051
7.

Fostering acceptance of human papillomavirus and herpes simplex virus vaccines among adolescents and parents.

Short MB, Rosenthal SL.

Curr Opin Pediatr. 2006 Feb;18(1):53-7. Review.

PMID:
16470163
8.

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.

Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.

Pharmacoeconomics. 2009;27(2):127-47. doi: 10.2165/00019053-200927020-00004. Review. Erratum in: Pharmacoeconomics. 2009;27(4):354.

PMID:
19254046
9.

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.

Harper DM.

Public Health Genomics. 2009;12(5-6):319-30. doi: 10.1159/000214922. Epub 2009 Aug 11. Review.

PMID:
19684444
10.

Human papillomavirus vaccines and anal carcinoma.

Franceschi S, De Vuyst H.

Curr Opin HIV AIDS. 2009 Jan;4(1):57-63. doi: 10.1097/COH.0b013e32831b9c81. Review.

PMID:
19339940
11.

Integrating human papillomavirus vaccination in cervical cancer control programmes.

Franco EL, Coutlée F, Ferenczy A.

Public Health Genomics. 2009;12(5-6):352-61. doi: 10.1159/000214925. Epub 2009 Aug 11. Review.

PMID:
19684447
12.

Human papillomavirus and the HPV vaccine: are the benefits worth the risks?

Knudtson M, Tiso S, Phillips S.

Nurs Clin North Am. 2009 Sep;44(3):293-9. doi: 10.1016/j.cnur.2009.06.005. Review.

PMID:
19683091
13.

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Syrjänen KJ.

Scand J Infect Dis Suppl. 2009;107:3-32. doi: 10.1080/00365540902887730. Review.

PMID:
19408160
14.

What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.

Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G.

Eur J Cancer. 2009 Oct;45(15):2714-21. doi: 10.1016/j.ejca.2009.07.024. Epub 2009 Aug 18. Review.

PMID:
19695870

Supplemental Content

Support Center